Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763376 | 0.85 | ALDH1A1 (0.69) | LMNARAB9AKMT2ALTC4SALDH1A1 | |
| SCHEMBL6766219 | 0.81 | POLB (0.72) | LMNARAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL16670942 | 0.78 | RAB9A (0.77) | LMNARAB9AKMT2AMEN1F2 | |
| SCHEMBL21533499 | 0.75 | LMNA (1.00) | LMNARAB9AKMT2AMEN1F2 | |
| SCHEMBL30083706 | 0.73 | LTC4S (0.56) | LMNARAB9AKMT2AMEN1LTC4S | |
| SCHEMBL8915482 | 0.73 | SMN1; SMN2 (0.62) | LMNARAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL8914946 | 0.73 | BCL6 (0.66) | LMNARAB9AALDH1A1NPSR1MAPT | |
| SCHEMBL7018134 | 0.72 | KMT2A (0.56) | LMNARAB9AKMT2AMEN1LTC4S | |
| SCHEMBL8914521 | 0.72 | ALDH1A1 (0.57) | LMNARAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL8915349 | 0.71 | SMN1; SMN2 (0.57) | LMNARAB9AKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727265-B2 | REVERSE TRANSCRIPTASE INHIBITORS FOR DRUG RESISTANT PATIENTS | PARKER HUGHES INSTITUTE | 2004-04-27 | — | — | US | disclosed |
| US-6689793-B2 | INHIBITORS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE AND MULTI-DRUG RESISTANT HUMAN IMMUNODEFICIENCY VIRUS REVERSE TRANSCRIPTASE | PARKER HUGHES INSTITUTE | 2004-02-10 | — | — | US | disclosed |
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | PARKER HUGHES INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| US-20020151568-A1 | Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity | PARKER HUGHES INSTITUTE | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151568-A1 | Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity | SAMHD1, PNP, NUDT1 | LMNA 4651/4885RAB9A 2832/4885KMT2A 622/4885 |
| US-20030186991-A1 | Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections | TPMT, TERT, TET1 | LMNA 4808/4885RAB9A 3227/4885KMT2A 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.